A potential novel combination therapy targeting survivin in renal cancer cells: Inhibition of survivin expression by topotecan and hexamethylene bisacetamide | NobleID
v1
A potential novel combination therapy targeting survivin in renal cancer cells: Inhibition of survivin expression by topotecan and hexamethylene bisacetamide.
Akinori Sato, Takako Asano, Keichi Ito, Makoto Sumitomoand 2 more